REPRIEVE Trial

¿Se pregunta cómo las personas con VIH pueden proteger la salud de su corazón? ¡Únase a nosotros para un foro comunitario virtual mañana a las 11:00 a. m., hora del este! https://www.reprievetrial.org/for-participants/community-forum/

The REPRIEVE Trial demonstrates that pitavastatin lowers the incidence rate of heart disease events by 35% in people with HIV. Read the results in :

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | NEJM Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

: Taking a daily statin medication has been found to reduce the excess risk of cardiovascular disease (CVD) among people living with HIV in , the first large-scale clinical trial testing a CVD preventive strategy in this population. Read the full NIH press release here:

Daily statin reduces the risk of cardiovascular disease in people living with HIV, large NIH study finds Premature heart disease and other chronic conditions have emerged as leading causes of morbidity and mortality.

In his statement, Dr. Fauci highlights how far we have come, how far we have yet to go, and acknowledges the important work of the REPRIEVE Trial. We are grateful to be a part of the continued HIV research efforts of the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID).
Click the link below to read the full statement from the NIH.

NIH Statement on World AIDS Day 2020 Today on World AIDS Day, we reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain. We now have highly effective HIV treatment and prevention methods, and work is underway to address the remaining challenges in delivering these tools...

On this we are reminded of the resilience of the HIV community, living through the HIV epidemic and the COVID-19 pandemic. The strength of the HIV community provides a beacon of hope and reminds us that we will get through this together.

Thank you to our community of participants, site investigators and staff who have remained dedicated to the safety of one another and the important research of the REPRIEVE Trial.

We know six manuscripts, plus an introduction piece, is a lot to read... So we summarized the findings for you! Click the link below to read summaries of findings from the baseline manuscripts published in The Journal of Infectious Diseases!

REPRIEVE Summaries of Findings September 2020 Summaries of articles in: Critical Comorbidities in the Modern Antiretroviral Era: Baseline Demographic, Metabolic, and Immune

Thank you to our REPRIEVE team and participants at CWRU AIDS Clinical Trials Unit!! REPRIEVE would not be a success without you - and all of our amazing clinical research sites and participants!

Large NIH Clinical Trial Illuminates Long-Term Health Effects of HIV With 7,770 participants enrolled in 12 countries across five continents, the REPRIEVE study is evaluating the ability of a statin medication to reduce the risk of heart disease among people with HIV. By leveraging data collected from this diverse group of study participants, researchers also are lea...